yahoo.comAUG 252 min read$PRE

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

Original reporting

yahoo.com

Published Aug 25, 2026, 2:30 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 25, 2026, 3:29 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Prenetics (PRE) Q2 2026 Earnings Call Transcript — source image — Source · yahoo.com

Decision brief

The 30-second read

$PREBullishMed

Why it matters

The earnings beat and guidance raise expectations for revenue growth and cash‑flow sustainability.

Market read

New earnings data and guidance lift the stock's short‑term outlook, making it a candidate for momentum trades.

What to watch

Potential supply‑chain constraints and regulatory approvals for new product lines.

Relevance 7/10Novelty 7/10Timing: post‑earnings release

Background

Prenetics (PRE) is a consumer‑health company that recently launched its IM8 supplement line.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PREBullishHigh confidence

Context

Prenetics reported Q2 2026 revenue of $46.5M and raised full‑year revenue guidance to $220‑230M, marking its first positive free‑cash‑flow quarter.

Expected impact

Potential upside of 5‑10% in the next few trading days.

Evidence & confidence

Guidance lift and cash‑flow positivity are material new facts for a growth‑stage company.

Market effects

Sector

Strengthens the consumer‑health and nutrition supplement sector outlook.

Regional

Positive for Hong Kong‑listed health‑tech firms.

Global

Limited to niche consumer‑health space.

Counterpoint

What could challenge this read

The guidance may be overly optimistic given the company's early stage and cash‑burn history.

Key entities

company
Prenetics Ltd
Consumer health and nutrition supplement provider.
investor
General Catalyst
Provided $1B commitment to support growth.

Read at source ← All news

AUG 18

$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.

yahoo.com7 min

AUG 18

$PREHighAI 9/10

Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted

Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.

finanznachrichten.de6 min

JUL 30

$PREMed

PartnerRe records $447m in first-half net income

PartnerRe reported first-half 2026 net income of $447 million, down from $493 million a year earlier, with operating income of $689 million and annualised operating ROE of 12.6%. Gross premiums written rose to $5.42 billion. Non-life underwriting profit was $396 million with a 85.1% combined ratio. Investment income increased to $491 million, but unrealised losses reduced net investment return.

royalgazette.com4 min

JUL 14

$PREMedAI 8/10

Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)

Prenetics Global Limited (NASDAQ: PRE) said IM8 closed a $1 billion growth financing facility from General Catalyst’s Customer Value Fund to finance up to 70% of IM8 marketing spend. Prenetics raised 2026 IM8 revenue guidance to $210-220 million and expects $300 million annualized by year-end 2026 and $400 million+ in 2027. No equity was issued.

manilatimes.net6 min

AUG 28

$HIMSHighAI 8/10

Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

yahoo.com2 min